CureVac’s Positive Preliminary Results for a COVID-19 Vaccine Showcases Important Canadian Connection

Vancouver, B.C. – German biotech firm CureVac has just announced positive preliminary results (https://bit.ly/34TK6Qn) from clinical studies on its COVID-19 vaccine, and it comes with a strong Canadian connection. Vancouver-based Acuitas Therapeutics is providing CureVac with a key element so that this urgently needed vaccine can be effective. Acuitas specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNP), which enable messenger RNA (mRNA) vaccines.

To help develop their COVID-19 vaccine, which uses mRNA technology, CureVac turned to its long-standing Canadian partner, Acuitas Therapeutics. Acuitas provides LNP – tiny “delivery vehicles” – that protect the mRNA vaccine after it is injected. In simple terms, Acuitas’ proprietary technology protects the vaccine after administration and delivers it into our cells, exactly where it needs to be. The Acuitas LNP delivery system is a key component of mRNA vaccines, and the company is playing a crucial role in the global race for a vaccine that will fight COVID-19.

About Acuitas Therapeutics

Founded in 2009, Vancouver-based Acuitas Therapeutics (www.acuitasTx.com) is a private biotechnology company that specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles. The company partners with pharmaceutical companies, biotechnology organizations and academic institutes to advance nucleic acid therapeutics to the clinical trial phase and to the marketplace. The team works with partners to develop new therapies to address unmet clinical needs based on its internationally recognized capabilities in delivery technology. Acuitas Therapeutics has multiple agreements in place for their proprietary lipid nanotechnology to be used in the development of several COVID-19 vaccines – with BioNTech (https://bit.ly/389FTdA) and now CureVac (https://bit.ly/34TK6Qn) publishing data from their clinical studies. An additional collaborator has also initiated clinical studies.

-END-